Evolus (EOLS) Competitors $11.40 -0.17 (-1.47%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS vs. MLTX, ALVO, IMVT, HCM, ACAD, APLS, AMRX, RXRX, IBRX, and BHVNShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include MoonLake Immunotherapeutics (MLTX), Alvotech (ALVO), Immunovant (IMVT), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Apellis Pharmaceuticals (APLS), Amneal Pharmaceuticals (AMRX), Recursion Pharmaceuticals (RXRX), ImmunityBio (IBRX), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Evolus vs. MoonLake Immunotherapeutics Alvotech Immunovant HUTCHMED ACADIA Pharmaceuticals Apellis Pharmaceuticals Amneal Pharmaceuticals Recursion Pharmaceuticals ImmunityBio Biohaven Evolus (NASDAQ:EOLS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, community ranking, dividends, earnings, institutional ownership and profitability. Does the media prefer EOLS or MLTX? In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Evolus. MarketBeat recorded 16 mentions for MoonLake Immunotherapeutics and 12 mentions for Evolus. Evolus' average media sentiment score of 1.55 beat MoonLake Immunotherapeutics' score of 0.84 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MoonLake Immunotherapeutics 4 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend EOLS or MLTX? Evolus currently has a consensus price target of $23.75, suggesting a potential upside of 108.33%. MoonLake Immunotherapeutics has a consensus price target of $80.50, suggesting a potential upside of 91.30%. Given Evolus' higher possible upside, analysts plainly believe Evolus is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evolus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00MoonLake Immunotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is EOLS or MLTX more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Evolus' net margin of -22.33%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Evolus-22.33% -847.60% -22.15% MoonLake Immunotherapeutics N/A -15.54%-15.09% Which has more volatility and risk, EOLS or MLTX? Evolus has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Which has stronger earnings & valuation, EOLS or MLTX? MoonLake Immunotherapeutics has lower revenue, but higher earnings than Evolus. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvolus$266.27M2.72-$61.69M-$0.81-14.07MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.89-22.26 Does the MarketBeat Community prefer EOLS or MLTX? Evolus received 293 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.14% of users gave MoonLake Immunotherapeutics an outperform vote while only 73.13% of users gave Evolus an outperform vote. CompanyUnderperformOutperformEvolusOutperform Votes36273.13% Underperform Votes13326.87% MoonLake ImmunotherapeuticsOutperform Votes6982.14% Underperform Votes1517.86% Do insiders and institutionals have more ownership in EOLS or MLTX? 90.7% of Evolus shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 6.1% of Evolus shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryMoonLake Immunotherapeutics beats Evolus on 11 of the 17 factors compared between the two stocks. Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$724.89M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-12.537.4522.4218.48Price / Sales2.72242.72394.10103.91Price / CashN/A65.8538.1834.62Price / Book-31.676.516.774.25Net Income-$61.69M$143.21M$3.22B$248.23M7 Day Performance1.51%3.97%3.26%3.29%1 Month Performance-5.39%0.37%0.02%2.42%1 Year Performance-3.14%2.60%18.01%5.54% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.8767 of 5 stars$11.40-1.5%$23.75+108.3%-3.1%$724.89M$266.27M-12.53170Upcoming EarningsNews CoverageMLTXMoonLake Immunotherapeutics1.5529 of 5 stars$40.00+4.4%$80.50+101.3%+2.9%$2.56BN/A-31.012Upcoming EarningsAnalyst ForecastNews CoverageALVOAlvotech1.7872 of 5 stars$8.33+0.5%$18.00+116.1%-45.9%$2.51B$489.68M-4.504Short Interest ↑IMVTImmunovant2.0508 of 5 stars$14.46-4.6%$41.00+183.5%-41.1%$2.46BN/A-5.52120Gap DownHigh Trading VolumeHCMHUTCHMED1.9431 of 5 stars$13.89+0.9%$19.00+36.8%-19.8%$2.42B$630.20M0.001,760Short Interest ↑ACADACADIA Pharmaceuticals4.2592 of 5 stars$14.38-2.4%$23.93+66.4%-12.6%$2.40B$957.80M18.44510Upcoming EarningsAnalyst ForecastAPLSApellis Pharmaceuticals4.1085 of 5 stars$18.03-0.9%$45.35+151.5%-56.5%$2.26B$781.37M-8.88770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageAMRXAmneal Pharmaceuticals3.3621 of 5 stars$7.13-3.1%$10.80+51.5%+26.6%$2.21B$2.79B-10.497,600News CoveragePositive NewsRXRXRecursion Pharmaceuticals2.2202 of 5 stars$5.41-1.6%$8.20+51.6%-28.5%$2.17B$58.49M-3.54400Upcoming EarningsGap DownIBRXImmunityBio1.6292 of 5 stars$2.51+1.6%$12.19+385.6%-68.6%$2.14B$14.75M-2.73590Upcoming EarningsAnalyst ForecastBHVNBiohaven3.6241 of 5 stars$20.67+1.5%$62.77+203.7%-43.0%$2.11BN/A-2.21239Upcoming EarningsAnalyst ForecastGap Down Related Companies and Tools Related Companies MoonLake Immunotherapeutics Competitors Alvotech Competitors Immunovant Competitors HUTCHMED Competitors ACADIA Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Recursion Pharmaceuticals Competitors ImmunityBio Competitors Biohaven Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EOLS) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
